Table 1 Characteristics of the study population before aHSCT
Characteristics | Values |
|---|---|
Female, % | 47.1 |
Age at aHSCT, median (range), years | 52.0 (23–64) |
Disease duration before aHSCT, median (range), years | 3.5 (0.3–13) |
Diffuse cutaneous form, % | 100 |
mRSS, median (range) points | 23.0 (5–44) |
Anti-nuclear antibody positivity, % | 88.2 |
Anti-Scl-70 antibody positivity, % | 64.7 |
Anti-Centromere antibody positivity, % | 0 |
Smoking history, % | |
Current | 5.9 |
Ever | 41.2 |
Pulmonary fibrosis on thoracic computed tomography, % | 82.4 |
FVC (% predicted) latest value before aHSCT, median (IQR) | 74.0 (58.0–89.0) |
DLCO (% predicted) latest value before aHSCT, median (IQR) | 44.0 (29.0–59.0) |
Troponin positivity, % | 82.4 |
Abnormal 24 h Holter ECG, n (%) | 1/15 (6.7) |
Abnormal cardiac MRI, n (%) | 6/13 (46.2) |
Right heart catheterization, done | 12/17 |
Pulmonal arterial hypertension, n (%) | 2/12 (16.7) |
Mean pulmonal arterial pressure (mPAP), mmHg, median (range) | 18.0 (9–30) |
Indication for aHSCT | |
Skin, % | 41.2 |
Lung, % | 35.3 |
Skin and lung, % | 23.5 |
Positive CMV-Serology, % | 35.3 |
Positive EBV-Serology, % | 100 |